Head-to-head · free

Ovid Therapeutics Inc. vs Quoin Pharmaceuticals

OVID vs QNRX — return on capital, cash generation, margins and balance sheet side by side.

OVID

1 / 3

measures where OVID leads

QNRX

2 / 3

measures where QNRX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureOVID · FY2025QNRX · FY2025
Revenue$7.3M—
Net income(17.4M)(15.8M)
Revenue growth (yearly, multi-year)-68.1%—
Free cash flow(38.3M)—
Free cash flow margin-528.6%—
Net cash / (debt)——
ROIC——
Return on equity-17.5%-141.6%
Gross margin——
Operating margin-585.2%—
Net debt / EBITDA0.31x0.24x

Figures are as reported by each company; latest fiscal year shown.

Where Ovid Therapeutics Inc.'s cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full OVID profile →

Where Quoin Pharmaceuticals's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full QNRX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons